BTG (LON:BTG)‘s stock had its “neutral” rating restated by investment analysts at J P Morgan Chase & Co in a report issued on Friday.

BTG has been the topic of several other reports. Peel Hunt restated a “hold” rating and set a GBX 680 ($9.15) target price on shares of BTG in a report on Wednesday, September 20th. Deutsche Bank restated a “buy” rating and set a GBX 775 ($10.43) target price on shares of BTG in a report on Friday, October 13th. Numis Securities restated a “buy” rating and set a GBX 900 ($12.11) target price on shares of BTG in a report on Thursday, October 5th. Finally, Stifel Nicolaus restated a “buy” rating and set a GBX 800 ($10.77) target price on shares of BTG in a report on Wednesday, August 30th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. BTG currently has a consensus rating of “Buy” and a consensus target price of GBX 771.63 ($10.39).

BTG (LON BTG) traded up GBX 16.98 ($0.23) on Friday, hitting GBX 731 ($9.84). The stock had a trading volume of 507,934 shares, compared to its average volume of 726,872. BTG has a one year low of GBX 528.36 ($7.11) and a one year high of GBX 779 ($10.48).

BTG (LON:BTG) last announced its quarterly earnings data on Tuesday, November 14th. The company reported GBX 21 ($0.28) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of GBX 21 ($0.28). BTG had a return on equity of 10.80% and a net margin of 15.50%. The business had revenue of £341.30 million during the quarter.

TRADEMARK VIOLATION WARNING: This report was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/12/10/j-p-morgan-chase-co-reiterates-neutral-rating-for-btg-btg.html.

About BTG

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.

Analyst Recommendations for BTG (LON:BTG)

Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with MarketBeat.com's FREE daily email newsletter.